Frosted Branch Angiitis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Old and New Challenges in Uveitis Associated with Behçet's Disease
Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. -
Un-Explained Visual Loss Following Silicone Oil Removal
Roca et al. Int J Retin Vitr (2017) 3:26 DOI 10.1186/s40942-017-0079-6 International Journal of Retina and Vitreous ORIGINAL ARTICLE Open Access Un‑explained visual loss following silicone oil removal: results of the Pan American Collaborative Retina Study (PACORES) Group Jose A. Roca1, Lihteh Wu2* , Maria Berrocal3, Francisco Rodriguez4, Arturo Alezzandrini5, Gustavo Alvira6, Raul Velez‑Montoya7, Hugo Quiroz‑Mercado7, J. Fernando Arevalo8, Martín Serrano9, Luiz H. Lima10, Marta Figueroa11, Michel Farah10 and Giovanna Chico1 Abstract Purpose: To report the incidence and clinical features of patients that experienced un-explained visual loss following silicone oil (SO) removal. Methods: Multicenter retrospective study of patients that underwent SO removal during 2000–2012. Visual loss of 2 lines was considered signifcant. ≥ Results: A total of 324 eyes of 324 patients underwent SO removal during the study period. Forty two (13%) eyes sufered a signifcant visual loss following SO removal. Twenty three (7.1%) of these eyes lost vision secondary to known causes. In the remaining 19 (5.9%) eyes, the loss of vision was not explained by any other pathology. Eleven of these 19 patients (57.9%) were male. The mean age of this group was 49.2 16.4 years. Eyes that had an un-explained visual loss had a mean IOP while the eye was flled with SO of 19.6 6.9 mm± Hg. The length of time that the eye was flled with SO was 14.8 4.4 months. In comparison, eyes that± did not experience visual loss had a mean IOP of 14 7.3 mm Hg (p < 0.0002)± and a mean tamponade duration of 9.3 10.9 months (p < 0.0001). -
Acute Hydrops Following Penetrating Keratoplasty in a Keratoconic Patient
Acute Hydrops following PK • Baradaran-Rafiee et al Iranian Journal of Ophthalmology • Volume 20 • Number 4 • 2008 Acute Hydrops following Penetrating Keratoplasty in a Keratoconic Patient Alireza Baradaran-Rafiee, MD1 • Manijeh Mahdavi, MD2 • Sepehr Feizi, MD3 Abstract Purpose: To report a case with history of penetrating keratoplasty (PK) for keratoconus that developed acute hydrops in the recipient and donor cornea Methods: A 46-year-old man, with history of bilateral keratoconus, who had undergone corneal transplantation in his left eye, presented with complaints of sudden visual reduction, photophobia, redness and pain of the left eye. Results: Review of his clinical course, slit-lamp biomicroscopy, laboratory evaluations including confocal microscopy and ultrasound biomicroscopy revealed acute hydrops in the graft. Second corneal transplantation was done for his left eye and pathologic examination confirmed the diagnosis. Conclusion: Acute hydrops can occur after PK in patients with keratoconus. Although this condition is not common, it should be considered as a differential diagnosis of graft rejection. Keywords: Acute Hydrops, Keratoconus, Corneal Transplantation Iranian Journal of Ophthalmology 2008;20(4):49-53 Introduction Keratoconus is a degenerative, One of the complications of advanced non-inflammatory disease of the cornea, with keratoconus is acute hydrops. Affected onset generally at puberty. It is progressive in patients suffer from acute visual loss with pain 20% of cases and can be treated by lamellar and photophobia. On slit-lamp examination, or penetrating keratoplasty (PK). Its incidence conjunctival hyperemia and diffuse corneal in general population is reported to be about edema with intrastromal cystic spaces are 1/2000.1 Changes in corneal collagen visible. -
Red Spot • Important Is the Time Period from the Event • Therapy Is Reasonable If the Patient Is Treated Within the First 6 Hours
ACUTE VISUAL LOSS KAROLÍNA SKORKOVSKÁ VISUAL LOSS • CENTRAL RETINAL ARTERY OCCLUSION • CENTRAL RETINAL VEIN OCCLUSION • RETINAL DETACHMENT • VITREOUS HAEMORRHAGE • OPTIC NEURITIS • AION VISUAL LOSS - PATIENT´S HISTORY • UNILATERAL / BILATERAL • SUDDEN / SLOWLY PROGRESSIVE • PAIN • COMPLAINTS (FOGGY VISION, FLOATERS, CURTAIN…) • OTHER SYMPTOMS (FEVER, WEIGHT LOSS, REFRACTIVE CHANGE, …) CATARACT • SLOWLY PROGRESSIVE VISUAL LOSS • FOGGY VISION • CHANGE IN REFRACTIVE ERROR (INDEX MYOPIA) • CATARACT VISIBLE ON SLIT LAMP • THERAPY: CATARACT EXTRACTION RETINAL ARTERY OCCLUSION • SUDDEN, UNILATERAL, PAINLESS LOSS OF VISION • VISUAL ACUITY MAY BE „NO LIGHT PERCEPTION“ • BRANCH / CENTRAL RETINAL ARTERY OCCLUSION • RETINAL ISCHEMIA WITH CHERRY RED SPOT • IMPORTANT IS THE TIME PERIOD FROM THE EVENT • THERAPY IS REASONABLE IF THE PATIENT IS TREATED WITHIN THE FIRST 6 HOURS RETINAL ARTERY OCCLUSION - COMPLICATIONS • POOR PROGNOSIS • PERMANENT LOSS OF VISION • OPTIC DISC ATROPHY • NEOVASCULARISATION GLAUCOMA RETINAL ARTERY OCCLUSION - THERAPY • LOWERING OF INTRAOCULAR PRESSURE • RETROBULBAR INJECTION OF VASODILATORS • PARACENTHESIS • SYSTEMIC TROMBOLYSIS (DEPARTMENT OF INTERNAL MEDICINE) • CHECK-UP OF RISK FACTORS OF ISCHEMIA / TROMBOSIS RETINAL VEIN OCCLUSION • SUDDEN, PAINLESS, UNILATERAL VISUAL LOSS • VISUAL ACUITY USUALLY NOT AS MUCH AFFECTED AS IN CRAO • BRANCH / CENTRAL RETINAL VEIN OCCLUSION • OFTEN CARDIOVASCULAR RISK FACTORS (HYPERTENSION, DIABETES, HYPERLIPIDEMIA, ISCHEMIC HEART DISEASE,…) • RETINAL HAEMORHAGES, OPTIC NERVE HEAD OEDEMA, RETINAL -
A Review of Central Retinal Artery Occlusion: Clinical Presentation And
Eye (2013) 27, 688–697 & 2013 Macmillan Publishers Limited All rights reserved 0950-222X/13 www.nature.com/eye 1 2 1 2 REVIEW A review of central DD Varma , S Cugati , AW Lee and CS Chen retinal artery occlusion: clinical presentation and management Abstract Central retinal artery occlusion (CRAO) is an that in turn place an individual at risk of future ophthalmic emergency and the ocular ana- cerebral stroke and ischaemic heart disease. logue of cerebral stroke. Best evidence reflects Although analogous to a cerebral stroke, there that over three-quarters of patients suffer is currently no guideline-endorsed evidence for profound acute visual loss with a visual acuity treatment. Current options for therapy include of 20/400 or worse. This results in a reduced the so-called ‘standard’ therapies, such as functional capacity and quality of life. There is sublingual isosorbide dinitrate, systemic also an increased risk of subsequent cerebral pentoxifylline or inhalation of a carbogen, stroke and ischaemic heart disease. There are hyperbaric oxygen, ocular massage, globe no current guideline-endorsed therapies, compression, intravenous acetazolamide and although the use of tissue plasminogen acti- mannitol, anterior chamber paracentesis, and vator (tPA) has been investigated in two methylprednisolone. None of these therapies randomized controlled trials. This review will has been shown to be better than placebo.5 describe the pathophysiology, epidemiology, There has been recent interest in the use of and clinical features of CRAO, and discuss tissue plasminogen activator (tPA) with two current and future treatments, including the recent randomized controlled trials on the 1Flinders Comprehensive use of tPA in further clinical trials. -
Relapsing Polychondritis
Relapsing polychondritis Author: Professor Alexandros A. Drosos1 Creation Date: November 2001 Update: October 2004 Scientific Editor: Professor Haralampos M. Moutsopoulos 1Department of Internal Medicine, Section of Rheumatology, Medical School, University of Ioannina, 451 10 Ioannina, GREECE. [email protected] Abstract Keywords Disease name and synonyms Diagnostic criteria / Definition Differential diagnosis Prevalence Laboratory findings Prognosis Management Etiology Genetic findings Diagnostic methods Genetic counseling Unresolved questions References Abstract Relapsing polychondritis (RP) is a multisystem inflammatory disease of unknown etiology affecting the cartilage. It is characterized by recurrent episodes of inflammation affecting the cartilaginous structures, resulting in tissue damage and tissue destruction. All types of cartilage may be involved. Chondritis of auricular, nasal, tracheal cartilage predominates in this disease, suggesting response to tissue-specific antigens such as collagen II and cartilage matrix protein (matrillin-1). The patients present with a wide spectrum of clinical symptoms and signs that often raise major diagnostic dilemmas. In about one third of patients, RP is associated with vasculitis and autoimmune rheumatic diseases. The most commonly reported types of vasculitis range from isolated cutaneous leucocytoclastic vasculitis to systemic polyangiitis. Vessels of all sizes may be affected and large-vessel vasculitis is a well-recognized and potentially fatal complication. The second most commonly associated disorder is autoimmune rheumatic diseases mainly rheumatoid arthritis and systemic lupus erythematosus . Other disorders associated with RP are hematological malignant diseases, gastrointestinal disorders, endocrine diseases and others. Relapsing polychondritis is generally a progressive disease. The majority of the patients experience intermittent or fluctuant inflammatory manifestations. In Rochester (Minnesota), the estimated annual incidence rate was 3.5/million. -
Birdshot Chorioretinopathy: Clinical Characteristics and Evolution*
Br J Ophthalmol: first published as 10.1136/bjo.72.9.646 on 1 September 1988. Downloaded from British Journal of Ophthalmology, 1988, 72, 646-659 Birdshot chorioretinopathy: clinical characteristics and evolution* HILDE A PRIEM'2 AND JENDO A OOSTERHUIS2 From the 'Eye Clinic, University ofGent, Belgium, and the 2Eye Clinic, University ofLeiden, The Netherlands SUMMARY During the period 1980-6 102 patients from 14 European eye clinics were diagnosed as having birdshot chorioretinopathy (BSCR). All were Caucasian, and the series consisted of 47 men and 55 women, with a mean age of 52*5 years. The major findings in this rare disorder concern the ocular fundus. Most marked are the patterned distribution of depigmented spots without hyperpigmentation, radiation from the optic disc in association with vitritis, retinal vasculopathy with frequent cystoid macular oedema, and involvement of the optic nerve head. The distribution and appearance of the lesions suggest that they are related to the major choroidal veins. Complications of the disease were epiretinal membranes, retinal neovascularisation, recurrent vitreous haemorrhage, subretinal neovascular membranes occurring both in the juxtapapillary and macular regions, and optic atrophy. The medical history was not contributory. HLA testing showed very strong disease association with HLA A29 (95.8%). The evidence suggests that it is a single disease a entity rather than group of disorders because of the remarkable similarity in the copyright. ophthalmological appearance and the clinical course, combined with the exceptionally high association with HLA A29. In 1980 a rare ocular disease was described by Ryan and Maumenee.' In the absence of a known aetiology, they chose the descriptive name 'birdshot http://bjo.bmj.com/ retinochoroidopathy' inspired by the unusual picture, which showed multiple small, cream coloured lesions, scattered mainly around the optic disc and radiating towards the equator, without hyperpigmentation at the level of the retinal pigment _ * epithelium. -
Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2
Rovenský et al. J Rheum Dis Treat 2016, 2:043 Volume 2 | Issue 4 Journal of ISSN: 2469-5726 Rheumatic Diseases and Treatment Review Article: Open Access Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2 1National Institute of Rheumatic Diseases, Piešťany, Slovak Republic 2Department of Rheumatology and Rehabilitation, Thomayer Hospital, Prague 4, Czech Republic *Corresponding author: Jozef Rovenský, National Institute of Rheumatic Diseases, Piešťany, Slovak Republic, E-mail: [email protected] of patients; in the systemic vasculitis subgroup survival is similar to Abstract that of patients with polyarteritis (up to about five years in 45% of Relapsing polychondritis (RP) is a rare immune-mediated disease patients). The period of survival is reduced mainly due to infection that may affect multiple organs. It is characterised by recurrent and respiratory compromise. episodes of inflammation of cartilaginous structures and other connective tissues, rich in glycosaminoglycan. Clinical symptoms Etiology and Pathogenesis concentrate in auricles, nose, larynx, upper airways, joints, heart, blood vessels, inner ear, cornea and sclera. The most prominent RP manifestation is inflammation of cartilaginous structures resulting in their destruction and fibrosis. Diagnosis of the disease is based on the Minnesota diagnostic criteria of 1986 and RP has to be suspected when the inflammatory It is characterised by a dense inflammatory infiltrate, composed bouts involve at least two of the typical sites - auricular, nasal, of neutrophil leukocytes, lymphocytes, macrophages and plasma laryngo-tracheal or one of the typical sites and two other - ocular, cells. At the onset, the disease affects only the perichondral area, statoacoustic disturbances (hearing loss and/or vertigo) and the inflammatory process gradually leads to loss of proteoglycans, arthritis. -
Acute Visual Loss 5 Cédric Lamirel , Nancy J
Acute Visual Loss 5 Cédric Lamirel , Nancy J. Newman , and Valérie Biousse Abstract Visual loss is a common symptom in neurologic emergencies. Although ocular causes of visual loss are usually identifi ed by eye care specialists, many patients appear in an emergency department or a neurologist’s offi ce when the ocular examination is normal or when it suggests a neurologic disorder. Indeed, many causes of monocular or binocular acute visual loss may reveal or precede a neurologic process. In this situation, a quick and simple clinical examination done at bedside in the emergency department allows the neurologist to localize the lesion and determine whether an urgent neurologic workup or further ophthalmologic consultation is necessary. Keywords Central retinal artery occlusion • Funduscopic examination • Optic neuropathy • Retinal emboli • Visual fi eld • Visual loss Acute vision changes typically precipitate emer- gency consultation. Although ocular causes are usually identifi ed by eye care specialists, many patients appear in an emergency department or a C. Lamirel , MD neurologist’s offi ce when the ocular examination Service d’ophtalmologie , Fondation Ophtalmologique is normal or when it suggests a neurologic disor- Adolphe Rothschild , Paris , France der. Indeed, many causes of monocular or binoc- e-mail: [email protected] ular acute visual loss may reveal or precede a N. J. Newman , MD • V. Biousse, MD () neurologic process. In this situation, a quick and Neuro-Ophthalmology Unit , simple clinical examination done at bedside in Emory University School of Medicine , Atlanta , GA , USA the emergency department allows the neurologist e-mail: [email protected]; [email protected] to localize the lesion and determine whether an K.L. -
Approach to Acute Visual Loss
APPROACH TO ACUTE VISUAL LOSS 11 : 2 Satish Khadilkar, Pramod Dhonde, Mumbai INTRODUCTION Acute visual loss is common in clinical practice. The symptom is very disturbing to patients and requires rapid clinical analysis and therapy, as it can be associated with significant morbidity. Etiologies of acute visual impairment range from retina to the occipital cortex, resulting in a plethora of presentations. For example in a case of retinal disease patient may feel as if a curtain is rising or dropping and in cases of occipital lesions, patients may give history of bumping into the objects without realization. Also, patients tend to mistake diplopia for visual loss, which needs careful analysis. Acute visual loss could either be monocular or binocular. Monocular loss is often related to local eye pathologies as glaucoma, uveitis, retinitis or neurological diseases like optic neuritis (ON) and anterior ischemic optic neuropathy (AION). Binocular diseases are usually associated with lesions affecting structures such as optic chiasma, lateral geniculate body, occipital radiations and occipital cortex. Pain is an important association of visual loss. Painful visual impairment is seen in ON, Tolosa Hunt Syndrome, orbital apex syndrome, pituitary apoplexy and glaucoma. On the other hand, diseases of the optic tracts, radiations, occipital cortex and AION tend to be painless. The natural history of the visual impairment is helpful in the differential diagnosis. Transient visual deficit is seen in vascular diseases, demyelinations, raised intracranial tension and hyper coagulable states. Lasting deficits are seen with, strokes, tumors and AION. Following cases will illustrate various clinical situations of acute visual impairment, encountered by clinicians. -
Visual Loss Due to Progressive Multifocal Leukoencephalopathy In
CLINICOPATHOLOGIC REPORTS, CASE REPORTS, AND SMALL CASE SERIES SECTION EDITOR: W. RICHARD GREEN, MD but there was a single nucleotide visible, fine-linear white scarring in Visual Loss Due to substitution (C155T) in exon 1 of this area (Figure 2). In the most se- Progressive Multifocal the WAS gene. verely affected gyri, the cortex was Leukoencephalopathy Six weeks later his vision was bi- also involved and had a darker color, in a Congenital lateral finger counting. A magnetic with apparent expansion and soften- resonance imaging (MRI) scan ing of its affected parts. Immunodeficiency Disorder showed scattered areas of white- Although the individual le- matter foci, predominantly peri- sions were present throughout the A 20-year-old man with Wiskott- pheral and not periventricular, on cerebral hemispheres, they were Aldrich syndrome (WAS) initially de- proton density and T2-weighted most frequent bilaterally in the oc- veloped a mild visual disturbance that scans. He was given intravenous cipital poles, which were also the progressed to blindness, increasing methylprednisolone sodium succi- major site of linear cortico–white- neurological deficits, and death nate because of the possibility of de- matter junction lesions and scar- within 4 months. Wiskott-Aldrich myelination. No improvement oc- ring as well as the regions of diffuse syndrome is an X-linked immuno- curred, and he was registered as blind. cortical involvement. A microsco- deficiency disorder characterized by Reduced sensation and generalized pic examination of the brain sec- thrombocytopenia, eczema, and sus- mild weakness (level 4-5) devel- tions showed small, spherical, white ceptibility to infection.1 This case il- oped in his right-hand side and face. -
Home>>Common Retinal & Ophthalmic Disorders
Common Retinal & Ophthalmic Disorders Cataract Central Serous Retinopathy Cystoid Macular Edema (Retinal Swelling) Diabetic Retinopathy Floaters Glaucoma Macular degeneration Macular Hole Macular Pucker - Epiretinal Membrane Neovascular Glaucoma Nevi and Pigmented Lesions of the Choroid Posterior Vitreous Detachment Proliferative Vitreoretinopathy (PVR) Retinal Tear and Detachment Retinal Artery and Vein Occlusion Retinitis Uveitis (Ocular Inflammation) White Dot Syndromes Anatomy and Function of the Eye (Short course in physiology of vision) Cataract Overview Any lack of clarity in the natural lens of the eye is called a cataract. In time, all of us develop cataracts. One experiences blurred vision in one or both eyes – and this cloudiness cannot be corrected with glasses or contact lens. Cataracts are frequent in seniors and can variably disturb reading and driving. Figure 1: Mature cataract: complete opacification of the lens. Cause Most cataracts are age-related. Diabetes is the most common predisposing condition. Excessive sun exposure also contributes to lens opacity. Less frequent causes include trauma, drugs (eg, systemic steroids), birth defects, neonatal infection and genetic/metabolic abnormalities. Natural History Age-related cataracts generally progress slowly. There is no known eye-drop, vitamin or drug to retard or reverse the condition. Treatment Surgery is the only option. Eye surgeons will perform cataract extraction when there is a functional deficit – some impairment of lifestyle of concern to the patient. Central Serous Retinopathy (CSR) Overview Central serous retinopathy is a condition in which a blister of clear fluid collects beneath the macula to cause acute visual blurring and distortion (Figure 2). Central serous retinochoroidopathy Left: Accumulation of clear fluid beneath the retina.